HCV Treatment
ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 07 September 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.
European Regulators Approve Daclatasvir for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 August 2014 00:00
- Written by HIVandHepatitis.com
The European Medicines Agency, which handles regulatory approval for 28 countries of the European Union, this week approved Bristol-Myers Squibb's hepatitis C virus NS5A inhibitor daclatasvir (Daklinza) for use in combination therapy for HCV genotypes 1, 2, 3, and 4.
Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C
- Details
- Category: Approved HCV Drugs
- Published on Friday, 22 August 2014 00:00
- Written by HIVandHepatitis.com
Vertex Pharmaceuticals announced last week that it will stop selling its HCV protease inhibitor telaprevir (Incivek or Incivo) as of October 16, 2014. While the first generation direct-acting antivirals are more effective than pegylated interferon plus ribavirin alone, they are no match for newer drugs such as Gilead Sciences' sofosbuvir (Sovaldi) or AbbVie's forthcoming "3D" regimen in terms of efficacy or tolerability.
Achillion HCV NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 August 2014 00:00
- Written by Achillion
An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.
Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 12 August 2014 00:00
- Written by HIVandHepatitis.com
An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.
Web Design and Development by